AllYouCanTech

Parkinson’s Study Discovers Current Cancer Medication as Possible Treatment

according to prior studies, researchers have identified that two additional proteins, Lag3 and Aplp1, collaborate to assist the propagation of the harmful alpha-synuclein aggregates into neuronal cells. In the course of that study, they found that removing Lag3 can hinder the process, decelerating it but failing to stop it altogether. The findings led them to realize that Lag3 was not the sole protein aiding the dissemination of toxic alpha-synuclein. Subsequently, they turned their attention to Aplp1, performing experiments with genetically altered mice that lacked one or both of the proteins. To facilitate their efforts, they utilized a drug that has already received FDA approval for cancer therapy, named nivolumab/relatlimab, which contains a Lag3 antibody. They uncovered that they could affect the interaction between the two proteins, potentially paving the way for a preventive treatment in the future. It is noteworthy that this involves a repurposed medication, similar to what could eventually contribute to an Alzheimer’s remedy, as suggested by another research project. A promising or effective treatment already exists. Additional studies are required to determine if and how it functions.